Drug Profile
Ledipasvir/sofosbuvir - Gilead Sciences
Alternative Names: GS 5885/PSI 7977; GS-5885/GS-7977; GS-5885/sofosbuvir; GS-7977/GS-5885; Harvoni; LDV/SOF; PSI 7977/GS 5885; Sofosbuvir/GS-5885; Sofosbuvir/ledipasvirLatest Information Update: 20 Apr 2023
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Developer Gilead Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health (USA); The French National Agency for Research on AIDS and Viral Hepatitis
- Class Amides; Antivirals; Azabicyclo compounds; Benzimidazoles; Carbamates; Fluorenes; Fluorinated hydrocarbons; Imidazoles; Phosphoric acid esters; Pyrimidine nucleotides; Small molecules; Spiro compounds
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis C
- Phase II Porphyria cutanea tarda
- No development reported Hepatitis B
Most Recent Events
- 19 Feb 2023 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Hepatitis C presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI-2023)
- 07 Dec 2022 No development reported - Phase-II for Hepatitis B in USA (PO)
- 07 Dec 2022 No development reported - Phase-II for Hepatitis C (Combination therapy, In children) in USA (PO)